Patents by Inventor Phillipp Lang

Phillipp Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas
    Patent number: 8546613
    Abstract: The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Rolf Gericke, Norbert Beier, Florian Lang, Phillipp Lang, Karl Lang
  • SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS
    Publication number: 20110060050
    Abstract: The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios.
    Type: Application
    Filed: February 17, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent GmbH
    Inventors: Thomas Fuchss, Rolf Gericke, Norbert Beier, Florian Lang, Phillipp Lang, Karl Lang
  • CLCKb mutation as a diagnostic therapeutical target
    Patent number: 7074573
    Abstract: The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceu
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: July 11, 2006
    Assignee: Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
    Inventors: Florian Lang, Siegfried Waldegger, Phillipp Lang, Angelika Lampert, Hannsjoerg Seybert, Nikola Jeck